First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
Jiayuan Zhang, Jingxun Wu, Shiangjiin Leaw, Yan Yu et al.
Journal
Oncology and Therapy
Topics
Cancer Immunotherapy and Biomarkers
article
First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
Jiayuan Zhang, Jingxun Wu, Shiangjiin Leaw, Yan Yu, Zhijie Wang, Rui Ma, Jie Wang, Yuanyuan Bao, Zhiyong Ma, Jiuwei Cui, Xinmin Yu, Jun Zhao
article en
Abstract
No abstract available for this paper.
Publication Tag
Oncology and Therapy
Institutions
Harbin Medical University (CN), Jilin University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Peking Union Medical College Hospital (CN), Zhengzhou University (CN), First Affiliated Hospital of Xiamen University (CN), Peking University Cancer Hospital (CN), Zhejiang Cancer Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), First Hospital of Jilin University (CN), Cancer Hospital of Chinese Academy of Medical Sciences (CN), Danone (China) (CN), Henan Cancer Hospital (CN), Liaoning Cancer Hospital & Institute (CN)